Stock research
TRVI Trevi Therapeutics, Inc.
Healthcare • Biotechnology
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This...…
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
3M change
+26.91%
Range high
$19.50
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in TRVI?
Price
Showing 3M history. Source: FMP historical price full.
- Prev Close
- $18.40
- Day High
- $18.49
- Day Low
- $17.64
- 52w High
- $20.22
- 52w Low
- $6.55
- Volume
- 1,350,335
- Avg Volume
- Beta
- 1.001
* TTM/most recent where available
Company
- Ticker
- TRVI
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Jennifer L. Good
- Employees
- 34
- Website
- www.trevitherapeutics.com
Key Metrics
- Market Cap
- 2.59B
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).